View Future GrowthGabather 과거 순이익 실적과거 기준 점검 0/6Gabather은 연평균 23.3%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 8.8%의 비율로 증가했습니다. 매출은 연평균 87.2%의 비율로 증가했습니다.핵심 정보23.29%순이익 성장률39.24%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률7.33%매출 성장률87.21%자기자본이익률-190.89%순이익률n/a최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Jun 04New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr6.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.8m free cash flow). Share price has been highly volatile over the past 3 months (555% average daily change). Shareholders have been substantially diluted in the past year (158% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€2.76m market cap, or US$3.20m).공시 • May 26Gabather AB (publ), Annual General Meeting, Jun 26, 2026Gabather AB (publ), Annual General Meeting, Jun 26, 2026, at 11:00 W. Europe Standard Time. Location: cerebrum conference room at forskargatan 20 g, building 212, floor 5, 151 36, sodertalje SwedenBoard Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Director Bert Junno was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Mar 18Gabather AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 4.16 million.Gabather AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 4.16 million. Security Name: Shares Security Type: Common Stock Securities Offered: 118,857,138 Price\Range: SEK 0.035 Transaction Features: Subsequent Direct Listing공시 • May 26Gabather AB (publ), Annual General Meeting, Jun 30, 2025Gabather AB (publ), Annual General Meeting, Jun 30, 2025, at 11:00 W. Europe Standard Time. Location: in the cerebrum conference room, at forskargatan 20 g, building 212, floor 5, 151 36 sodertalje. Sweden공시 • Mar 20Gabather AB (publ) has completed a Composite Units Offering.Gabather AB (publ) has completed a Composite Units Offering. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 7,081,046 Price\Range: SEK 0.9 Transaction Features: Rights OfferingNew Risk • Sep 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr8.7m free cash flow). Share price has been highly volatile over the past 3 months (42% average weekly change). Negative equity (-kr3.6m). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€1.44m market cap, or US$1.59m).New Risk • Jun 04New major risk - Negative shareholders equityThe company has negative equity. Total equity: -kr2.7m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Share price has been highly volatile over the past 3 months (49% average weekly change). Negative equity (-kr2.7m). Revenue is less than US$1m. Market cap is less than US$10m (€2.72m market cap, or US$2.96m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding).공시 • May 31Gabather AB (publ), Annual General Meeting, Jun 28, 2024Gabather AB (publ), Annual General Meeting, Jun 28, 2024, at 14:00 W. Europe Standard Time. Location: in conference room cerebrum at forskargatan 20, g, bygg 212, floor 5, 151 36, sodertalje Sweden공시 • Mar 21Gabather AB Files Two New Patent Applications to Secure Novel Findings on the Effects of GT-002 for the Treatment of Neuropsychiatric DisordersGabather AB reported that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor modulator. The inventions relate to the medical use of GT-002 in psychiatric disorders. The claims based on inventions from the results from the company's EEG/fMRI target engagement study are both novel and unexpected and will strengthen Gabather’s intellectual property right (IPR) position in the field of GABAA receptor modulators, and the medical use of GT-002. The company's IPR strategy is to build layers of patents around the company's drug products, generating a strong and attractive IPR position for the products that generates an extended patent protection of the drug product. Gabather has an active portfolio of patents and patent applications covering key products and methods that create significant value to the company, giving Gabather the freedom to operate, product differentiation, as well as a strong negotiation position in potential agreement negotiations. GT-002 is a small molecule GABAA receptor Positive Allosteric Modulator (PAM) eliciting both tonic and phasic inhibitory currents. GT-002 improves learning and memory in preclinical models. It restores ketamine induced cognitive deficits in the discrimination learning task model, and inhibits the behavioural effects induced by phencyclidine in the in-vivo model of schizophrenia. GT-002 has been shown to be anxiolytic and to promote social interaction in rats. GT-002 targets a novel binding site on GABAA receptors, different from benzodiazepines (BZD), and has not shown any of the side effects known for BZD. Long-term treatment (28 days) with GT-002 has not shown any withdrawal symptoms upon cessation of treatment both in mice and dogs, indicating no drug abuse liability associated with this drug candidate. GT-002 has completed 3 phase I clinical trials in healthy volunteers. Both single ascending dose (SAD) and multiple ascending dose (MAD) studies have been completed. The results from these studies show that GT-002 is safe and well tolerated and that it has excellent pharmacokinetics, allowing for once-a-day oral dosing. An EEG/fMRI target engagement study in healthy volunteers aimed to determine the effects of GT-002 on brain activity across different brain regions and neuronal networks has recently been completed.공시 • Mar 07Gabather AB (publ) Reports Initial Positive Results from the EEG/fMRI Target Engagement StudyGabather AB reported initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers. The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002. The secondary objective to demonstrate target engagement in human brain was also met. The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders. Clinically relevant effects of GT-002 were observed on modulation of EEG frequency band power with a significant increase in alpha band power, compared to Lorazepam at the 2-hour after treatment. This effect spanned various brain regions, including frontal and occipital areas. No significant effect of Lorazepam on EEG alpha band power compared to placebo was observed. The results suggest a distinct effect of GT-002 to modulate alpha band power across specific cortical regions. EEG alpha band power is recognized as a marker of cognitive activity such as attention and associated with relaxation and less anxiety, an increase in alpha band may be beneficial for a number of different neuropsychiatric conditions. Of particular clinical interest are the reports that negative symptoms in schizophrenia patients are associated with reduced EEG alpha band power.공시 • Dec 14Gabather AB Approaches a Significant Milestone in the Clinical Development of GT-002Gabather AB approaching a significant milestone in the clinical development of GT-002. The Company has completed 3 clinical trials so far, each showing that GT-002 is safe and well tolerated in man. The next step in the development of GT-002 is clinical studies in patients with diagnoses where effective treatments are lacking. Discussions with specialist doctors and researchers at the Karolinska Institutet have been initiated for the design of a study in individuals with genetic predispositions to develop FTD. Currently, there are no available specific treatments for FTD, and there is still no evidence of an effective symptomatic treatment. The goal is to create ground-breaking symptomatic treatment of FTD. The intended study is a pilot study with the aim of laying the foundation for a larger multi-centre study with GT-002. At the same time, Gabather is working towards orphan drug status "Orphan Drug Designation" (ODD) for GT-002, with a planned advisory meeting with the European Medicines Agency (EMA) during the first quarter of 2024. ODD enables a faster review and approval of the drug candidate, which also creates new opportunities for licensing deals.공시 • Oct 13Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy VolunteersGabather announced the completion of the clinical phase of the EEG/fMRI target engagement study of GT-002 in healthy volunteers. All subjects have received the treatments, and the results show that GT-002 was well-tolerated with a favourable safety profile. The safety data confirms previous results from the two Phase 1 studies, the single ascending dose (SAD) study, and the multiple ascending dose (MAD) study with GT-002. The EEG/fMRI study was designed to evaluate the safety, tolerability, pharmacokinetics, target engagement and functional connectivity of brain networks of GT-002. The study included 26 healthy volunteer subjects, of which 17 subjects completed all treatments. Data analysis is currently in progress, and the final study report, including the EEG/fMRI results, will be available once 2CA-Braga has completed the comprehensive analysis of all the collected data. In parallel with the data analysis, preparations for the continued clinical development of GT-002 is ongoing.Board Change • Nov 16Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Olov Sterner is the most experienced director on the board, commencing their role in 2014. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.공시 • May 18Gabather Receives Approval to Start the EEG/fMRI Target Engagement Study with the Drug Candidate GT-002Gabather AB announces that the company has received approval from the Portuguese regulatory authority, INFARMED, to start the target-engagement study in healthy volunteers with the drug candidate GT-002. Screening and recruitment of individuals will start shortly. GT-002 is the most advanced selective GABAA receptor modulator with a unique mechanism of action that opens for the development of new and effective drugs against several neuropsychiatric diagnoses. In the double-blind, placebo-controlled phase 1 study, healthy subjects will receive GT-002 in a so-called cross-over design study where the effect of GT-002 will be examined with electroencephalography (EEG) and magnetic resonance imaging (fMRI). The aim of the study is to investigate the effects of GT-002 on EEG signals and the location of the signals in the human brain.Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Olov Sterner is the most experienced director on the board, commencing their role in 2014. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Board Change • Jan 21Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Olov Sterner is the most experienced director on the board, commencing their role in 2014. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Is New 90 Day High Low • Feb 05New 90-day high: €0.63The company is up 10.0% from its price of €0.57 on 06 November 2020. The German market is up 14% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 10.0% over the same period.Is New 90 Day High Low • Dec 15New 90-day low: €0.51The company is down 24% from its price of €0.67 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Nov 19New 90-day low: €0.55The company is down 32% from its price of €0.81 on 20 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.매출 및 비용 세부 내역Gabather가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:5J2 매출, 비용 및 순이익 (SEK Millions)날짜매출순이익일반관리비연구개발비31 Mar 260-55031 Dec 250-55030 Sep 250-55030 Jun 250-55031 Mar 250-55031 Dec 240-88030 Sep 240-99030 Jun 240-1111031 Mar 240-1111031 Dec 230-99030 Sep 230-99030 Jun 230-88031 Mar 230-99031 Dec 220-99030 Sep 220-1111030 Jun 220-1313031 Mar 220-1515031 Dec 210-1717030 Sep 210-1515030 Jun 210-1615031 Mar 210-1414031 Dec 200-1515030 Sep 200-1515030 Jun 200-1313031 Mar 200-1515031 Dec 190-1414030 Sep 190-1514030 Jun 190-1717031 Mar 190-1919031 Dec 180-2020030 Sep 180-2121030 Jun 180-1920031 Mar 18-1-1518031 Dec 170-1417030 Sep 170-1215030 Jun 170-1012031 Mar 171-911031 Dec 160-88030 Sep 160-77030 Jun 160-77031 Mar 160-660양질의 수익: 5J2 은(는) 현재 수익성이 없습니다.이익 마진 증가: 5J2는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 5J2는 수익성이 없지만 지난 5년 동안 연평균 23.3%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 5J2의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 5J2은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(15.3%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 5J2는 현재 수익성이 없으므로 자본 수익률이 음수(-190.89%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/17 09:53종가2026/06/17 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Gabather AB (publ)는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • Jun 04New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr6.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.8m free cash flow). Share price has been highly volatile over the past 3 months (555% average daily change). Shareholders have been substantially diluted in the past year (158% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€2.76m market cap, or US$3.20m).
공시 • May 26Gabather AB (publ), Annual General Meeting, Jun 26, 2026Gabather AB (publ), Annual General Meeting, Jun 26, 2026, at 11:00 W. Europe Standard Time. Location: cerebrum conference room at forskargatan 20 g, building 212, floor 5, 151 36, sodertalje Sweden
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Director Bert Junno was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Mar 18Gabather AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 4.16 million.Gabather AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 4.16 million. Security Name: Shares Security Type: Common Stock Securities Offered: 118,857,138 Price\Range: SEK 0.035 Transaction Features: Subsequent Direct Listing
공시 • May 26Gabather AB (publ), Annual General Meeting, Jun 30, 2025Gabather AB (publ), Annual General Meeting, Jun 30, 2025, at 11:00 W. Europe Standard Time. Location: in the cerebrum conference room, at forskargatan 20 g, building 212, floor 5, 151 36 sodertalje. Sweden
공시 • Mar 20Gabather AB (publ) has completed a Composite Units Offering.Gabather AB (publ) has completed a Composite Units Offering. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 7,081,046 Price\Range: SEK 0.9 Transaction Features: Rights Offering
New Risk • Sep 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr8.7m free cash flow). Share price has been highly volatile over the past 3 months (42% average weekly change). Negative equity (-kr3.6m). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€1.44m market cap, or US$1.59m).
New Risk • Jun 04New major risk - Negative shareholders equityThe company has negative equity. Total equity: -kr2.7m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Share price has been highly volatile over the past 3 months (49% average weekly change). Negative equity (-kr2.7m). Revenue is less than US$1m. Market cap is less than US$10m (€2.72m market cap, or US$2.96m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding).
공시 • May 31Gabather AB (publ), Annual General Meeting, Jun 28, 2024Gabather AB (publ), Annual General Meeting, Jun 28, 2024, at 14:00 W. Europe Standard Time. Location: in conference room cerebrum at forskargatan 20, g, bygg 212, floor 5, 151 36, sodertalje Sweden
공시 • Mar 21Gabather AB Files Two New Patent Applications to Secure Novel Findings on the Effects of GT-002 for the Treatment of Neuropsychiatric DisordersGabather AB reported that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor modulator. The inventions relate to the medical use of GT-002 in psychiatric disorders. The claims based on inventions from the results from the company's EEG/fMRI target engagement study are both novel and unexpected and will strengthen Gabather’s intellectual property right (IPR) position in the field of GABAA receptor modulators, and the medical use of GT-002. The company's IPR strategy is to build layers of patents around the company's drug products, generating a strong and attractive IPR position for the products that generates an extended patent protection of the drug product. Gabather has an active portfolio of patents and patent applications covering key products and methods that create significant value to the company, giving Gabather the freedom to operate, product differentiation, as well as a strong negotiation position in potential agreement negotiations. GT-002 is a small molecule GABAA receptor Positive Allosteric Modulator (PAM) eliciting both tonic and phasic inhibitory currents. GT-002 improves learning and memory in preclinical models. It restores ketamine induced cognitive deficits in the discrimination learning task model, and inhibits the behavioural effects induced by phencyclidine in the in-vivo model of schizophrenia. GT-002 has been shown to be anxiolytic and to promote social interaction in rats. GT-002 targets a novel binding site on GABAA receptors, different from benzodiazepines (BZD), and has not shown any of the side effects known for BZD. Long-term treatment (28 days) with GT-002 has not shown any withdrawal symptoms upon cessation of treatment both in mice and dogs, indicating no drug abuse liability associated with this drug candidate. GT-002 has completed 3 phase I clinical trials in healthy volunteers. Both single ascending dose (SAD) and multiple ascending dose (MAD) studies have been completed. The results from these studies show that GT-002 is safe and well tolerated and that it has excellent pharmacokinetics, allowing for once-a-day oral dosing. An EEG/fMRI target engagement study in healthy volunteers aimed to determine the effects of GT-002 on brain activity across different brain regions and neuronal networks has recently been completed.
공시 • Mar 07Gabather AB (publ) Reports Initial Positive Results from the EEG/fMRI Target Engagement StudyGabather AB reported initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers. The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002. The secondary objective to demonstrate target engagement in human brain was also met. The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders. Clinically relevant effects of GT-002 were observed on modulation of EEG frequency band power with a significant increase in alpha band power, compared to Lorazepam at the 2-hour after treatment. This effect spanned various brain regions, including frontal and occipital areas. No significant effect of Lorazepam on EEG alpha band power compared to placebo was observed. The results suggest a distinct effect of GT-002 to modulate alpha band power across specific cortical regions. EEG alpha band power is recognized as a marker of cognitive activity such as attention and associated with relaxation and less anxiety, an increase in alpha band may be beneficial for a number of different neuropsychiatric conditions. Of particular clinical interest are the reports that negative symptoms in schizophrenia patients are associated with reduced EEG alpha band power.
공시 • Dec 14Gabather AB Approaches a Significant Milestone in the Clinical Development of GT-002Gabather AB approaching a significant milestone in the clinical development of GT-002. The Company has completed 3 clinical trials so far, each showing that GT-002 is safe and well tolerated in man. The next step in the development of GT-002 is clinical studies in patients with diagnoses where effective treatments are lacking. Discussions with specialist doctors and researchers at the Karolinska Institutet have been initiated for the design of a study in individuals with genetic predispositions to develop FTD. Currently, there are no available specific treatments for FTD, and there is still no evidence of an effective symptomatic treatment. The goal is to create ground-breaking symptomatic treatment of FTD. The intended study is a pilot study with the aim of laying the foundation for a larger multi-centre study with GT-002. At the same time, Gabather is working towards orphan drug status "Orphan Drug Designation" (ODD) for GT-002, with a planned advisory meeting with the European Medicines Agency (EMA) during the first quarter of 2024. ODD enables a faster review and approval of the drug candidate, which also creates new opportunities for licensing deals.
공시 • Oct 13Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy VolunteersGabather announced the completion of the clinical phase of the EEG/fMRI target engagement study of GT-002 in healthy volunteers. All subjects have received the treatments, and the results show that GT-002 was well-tolerated with a favourable safety profile. The safety data confirms previous results from the two Phase 1 studies, the single ascending dose (SAD) study, and the multiple ascending dose (MAD) study with GT-002. The EEG/fMRI study was designed to evaluate the safety, tolerability, pharmacokinetics, target engagement and functional connectivity of brain networks of GT-002. The study included 26 healthy volunteer subjects, of which 17 subjects completed all treatments. Data analysis is currently in progress, and the final study report, including the EEG/fMRI results, will be available once 2CA-Braga has completed the comprehensive analysis of all the collected data. In parallel with the data analysis, preparations for the continued clinical development of GT-002 is ongoing.
Board Change • Nov 16Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Olov Sterner is the most experienced director on the board, commencing their role in 2014. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
공시 • May 18Gabather Receives Approval to Start the EEG/fMRI Target Engagement Study with the Drug Candidate GT-002Gabather AB announces that the company has received approval from the Portuguese regulatory authority, INFARMED, to start the target-engagement study in healthy volunteers with the drug candidate GT-002. Screening and recruitment of individuals will start shortly. GT-002 is the most advanced selective GABAA receptor modulator with a unique mechanism of action that opens for the development of new and effective drugs against several neuropsychiatric diagnoses. In the double-blind, placebo-controlled phase 1 study, healthy subjects will receive GT-002 in a so-called cross-over design study where the effect of GT-002 will be examined with electroencephalography (EEG) and magnetic resonance imaging (fMRI). The aim of the study is to investigate the effects of GT-002 on EEG signals and the location of the signals in the human brain.
Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Olov Sterner is the most experienced director on the board, commencing their role in 2014. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Board Change • Jan 21Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Olov Sterner is the most experienced director on the board, commencing their role in 2014. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Is New 90 Day High Low • Feb 05New 90-day high: €0.63The company is up 10.0% from its price of €0.57 on 06 November 2020. The German market is up 14% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 10.0% over the same period.
Is New 90 Day High Low • Dec 15New 90-day low: €0.51The company is down 24% from its price of €0.67 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Nov 19New 90-day low: €0.55The company is down 32% from its price of €0.81 on 20 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.